Core Insights - Klotho Neurosciences, Inc. is advancing Klotho-based therapeutics for neurodegenerative diseases, targeting a market estimated at over $8 billion annually for conditions like ALS, Alzheimer's, and Parkinson's disease [1][2] Group 1: Company Achievements - In 2025, Klotho Neurosciences achieved critical strategic and operational milestones, executing a focused strategy to advance Klotho-based therapeutics from preclinical development toward clinical evaluation [2] - The company has enhanced its operational and scientific foundations through strategic partnerships, expanded research capabilities, and the addition of key talent [2] - Klotho is positioned to pursue key objectives that build on its 2025 successes, aiming to create long-term value for shareholders [2] Group 2: Product Development - Klotho Neurosciences focuses on innovative, disease-modifying cell and gene therapies derived from the human Klotho gene, targeting neurodegenerative and age-related disorders [3] - The current portfolio includes proprietary cell and gene therapy programs using DNA and RNA as therapeutics, along with genomics-based diagnostic assays [3] Group 3: Future Plans - The company plans to accelerate preclinical and IND-enabling studies for its KLTO-202 program [5] - Klotho aims to evaluate complementary technologies and acquisitions to enhance its pipeline breadth in brain health, organ function, and longevity [5] - The company will continue to expand internal capabilities to strengthen R&D, manufacturing, and clinical readiness [5]
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market